Navigation Links
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Date:5/9/2008

The most common treatment emergent adverse events for both groups were nausea, vomiting, dizziness, constipation, headache, and somnolence (drowsiness). While the incidence of nausea, vomiting, constipation and the composite nausea and vomiting were significantly lower in the tapentadol IR treated groups compared to the oxycodone IR groups, the incidences of dizziness and somnolence (drowsiness) were not significantly different between the treatment groups.

"Gastrointestinal side effects, such as constipation, from centrally acting opioid pain medicines can be a treatment complication for pain patients and their healthcare professionals," said David Upmalis, M.D., Senior Director, CNS/Pain, J&JPRD. "Our study shows that tapentadol IR may offer improved gastrointestinal tolerability compared to other strong pain medications. Such a difference could improve patient treatment, and provide healthcare professionals an additional therapeutic option to treat acute pain."

Tapentadol is a novel investigational, centrally acting oral analgesic. It has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for chronic pain.

The use of tapentadol IR for the treatment of moderate to severe acute pain is under review by the United States Food and Drug Administration. The New Drug Application (NDA) was filed on January 23, 2008. Upon FDA approval, PriCara(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market tapentadol in the United States. The NDA filing is part of the ongoing commitment of J&JPRD and PriCara(TM) to bring new and innovative products to patients and physicians for the treatment and management of pain.

Study Design

This Phase 3, double-blind, randomized, active-control, parallel group, multi-center trial of 878 pa
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
4. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
5. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
9. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral ... Executive Officer, will present live at VirtualInvestorConferences.com on ... 6, 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... live, interactive online event where investors are invited ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... Piper Jaffray Health Care Conference on Wednesday, November 30, ... Palace Hotel in New York. The presentation will be ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: The 2011 Vibrio Diagnostics ... Forecasts by Country http://www.reportlinker.com/p0444741/The-Vibrio-Diagnostics-Market-US-Europe-JapanTest-Volume-and-Sales-Forecasts-by-Country.html ... detailed analysis of the Vibrio diagnostics market in ...
Cached Medicine Technology:The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 2The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 3The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 4
(Date:8/4/2015)... Angeles, CA (PRWEB) , ... August 04, 2015 , ... ... study that found financial incentives to be a viable method for encouraging people to ... wager money on the future of their weight loss success, adding a financial incentive ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... ... 04, 2015 , ... Members receiving care from a doctor who participates in ... that is nine percent lower -- than those members at traditional doctor practices, according ... programs. , “The promise of patient-centered, or value-based, care to deliver better quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are researching online ... physician. In an effort to share more and better information with these savvy ... publicly share patient satisfaction ratings and comments about its doctors and advanced practice ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... you are pregnant, here,s another reason to work out: ... developing neurodegenerative diseases, such as Alzheimer,s, later in life. ... FASEB Journal ( http://www.fasebj.org ) shows that mice ... Alzheimer,s disease showed fewer signs of the disease and ...
... of the leading causes of death and morbidity worldwide, ... 2008, the worldwide cost of cancer due to premature ... to be US$895 billion. An expert report from ... of some of the world,s leading cancer specialists, from ...
... Netherlands: Mothers who are exposed to particular agents during pregnancy ... asthma, according to new research. The study will ... Society,s Annual Congress in Amsterdam. It is ... and chemicals it can cause asthma. However, there has been ...
... The Netherlands: A new study has shown that people ... reduced lung function are at a serious risk of ... presented today (26 September 2011) at the European Respiratory ... COPD and reduced lung function should be routinely screened ...
... and unspoken clues exchanged by patients and doctors exert ... study by the University of Michigan Health System. Researchers ... interviews with participants to help elucidate signals sent and ... The method shows promise for improving medical decision ...
... of personalised medicine, gains in cancer survival over the ... trials with less stringent evidence criteria, a researcher told ... 26 Sept). The introduction of targeted treatments means ... most effective way of getting new treatments to cancer ...
Cached Medicine News:Health News:Pregnant women who exercise protect their offspring against long-term neurodegenerative diseases 2Health News:Unequal access to cancer care can no longer be tolerated 2Health News:Unequal access to cancer care can no longer be tolerated 3Health News:A mother's occupation while pregnant can cause asthma in children 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 3Health News:Smaller, faster trials can improve cancer patient survival 2Health News:Smaller, faster trials can improve cancer patient survival 3
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Sickle Edge blade, straight, 5.0 mm W x 84 mm long. Specially designed for superior visibility and easy access into the ear canal, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: